{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T15:19:18Z","timestamp":1790263158752,"version":"4.1.0"},"reference-count":33,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,1,14]]},"DOI":"10.1097\/qad.0000000000000060","type":"journal-article","created":{"date-parts":[[2013,12,20]],"date-time":"2013-12-20T10:03:00Z","timestamp":1387533780000},"page":"201-208","source":"Crossref","is-referenced-by-count":17,"title":["Cellular HIV reservoir replenishment is not affected by blip or intermittent viremia episodes during darunavir\/ritonavir monotherapy"],"prefix":"10.1097","volume":"28","author":[{"given":"Almudena","family":"Torres-Cornejo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar J.","family":"BenMarzouk-Hidalgo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia","family":"Guti\u00e9rrez-Valencia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pilar","family":"P\u00e9rez-Romero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reyes","family":"Mart\u00edn-Pe\u00f1a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa","family":"Ruiz-Valderas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pompeyo","family":"Viciana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis F.","family":"Lopez-Cortes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-6-20210130","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1111\/j.1468-1293.2012.00989.x","article-title":"The MONET trial: week 144 analysis of the efficacy of darunavirritonavir (DRVr) monotherapy versus DRVr plus two nucleoside reverse transcriptase inhibitors, for patients with viral load 50 HIV-1 RNA copiesmL at baseline.","volume":"13","author":"Arribas","year":"2012","journal-title":"HIV Med"},{"key":"R2-6-20210130","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1097\/QAD.0b013e3283348944","article-title":"The MONET trial: darunavirritonavir with or without nucleoside analogues, for patients with HIV RNA below 50copiesml.","volume":"24","author":"Arribas","year":"2010","journal-title":"AIDS"},{"key":"R3-6-20210130","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1097\/QAD.0b013e328345ee95","article-title":"Week 48 analysis of once-daily vs. twice-daily darunavirritonavir in treatment-experienced HIV-1-infected patients.","volume":"25","author":"Cahn","year":"2011","journal-title":"AIDS"},{"key":"R4-6-20210130","doi-asserted-by":"crossref","first-page":"e23726","DOI":"10.1371\/journal.pone.0023726","article-title":"Pilot, randomized study assessing safety, tolerability and efficacy of simplified LPVr maintenance therapy in HIV patients on the 1 PI-based regimen.","volume":"6","author":"Cahn","year":"2011","journal-title":"PLoS One"},{"key":"R5-6-20210130","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1086\/589622","article-title":"A 96-week comparison of lopinavir-ritonavir combination therapy followed by lopinavir-ritonavir monotherapy versus efavirenz combination therapy.","volume":"198","author":"Cameron","year":"2008","journal-title":"J Infect Dis"},{"key":"R6-6-20210130","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1097\/QAD.0b013e32833db9a1","article-title":"Randomized controlled study demonstrating failure of LPVr monotherapy in HIV: the role of compartment and CD4-nadir.","volume":"24","author":"Gutmann","year":"2010","journal-title":"AIDS"},{"key":"R7-6-20210130","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1097\/QAD.0b013e32833dec20","article-title":"Efficacy of darunavirritonavir maintenance monotherapy in patients with HIV-1 viral suppression: a randomized open-label, noninferiority trial, MONOI-ANRS 136.","volume":"24","author":"Katlama","year":"2010","journal-title":"AIDS"},{"key":"R8-6-20210130","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1093\/jac\/dkq327","article-title":"Lopinavirritonavir monotherapy versus current treatment continuation for maintenance therapy of HIV-1 infection: the KALESOLO trial.","volume":"65","author":"Meynard","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"R9-6-20210130","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1310\/hct1006-368","article-title":"Monotherapy with LopinavirRitonavir as maintenance after HIV-1 viral suppression: results of a 96-week randomized, controlled, open-label, pilot trial (KalMo study).","volume":"10","author":"Nunes","year":"2009","journal-title":"HIV Clin Trials"},{"key":"R10-6-20210130","doi-asserted-by":"crossref","first-page":"F1","DOI":"10.1097\/QAD.0b013e3282f4243b","article-title":"Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and two nucleosides for maintenance therapy of HIV.","volume":"22","author":"Pulido","year":"2008","journal-title":"AIDS"},{"key":"R11-6-20210130","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1093\/jac\/dkr504","article-title":"Long-term efficacy of darunavirritonavir monotherapy in patients with HIV-1 viral suppression: week 96 results from the MONOI ANRS 136 study.","volume":"67","author":"Valantin","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"R12-6-20210130","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1093\/infdis\/jir518","article-title":"Factors associated with virological failure in HIV-1-infected patients receiving darunavirritonavir monotherapy.","volume":"204","author":"Lambert-Niclot","year":"2011","journal-title":"J Infect Dis"},{"key":"R13-6-20210130","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1097\/QAD.0b013e32830fbdbc","article-title":"HIV-DNA in rectal cells is well correlated with HIV-DNA in blood in different groups of patients, including long-term nonprogressors.","volume":"22","author":"Avettand-Fenoel","year":"2008","journal-title":"AIDS"},{"key":"R14-6-20210130","doi-asserted-by":"crossref","first-page":"12574","DOI":"10.1073\/pnas.94.23.12574","article-title":"Reduction of HIV-1 in blood and lymph nodes following potent antiretroviral therapy and the virologic correlates of treatment failure.","volume":"94","author":"Wong","year":"1997","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R15-6-20210130","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1097\/00002030-200411190-00006","article-title":"Cellular HIV-1 DNA load predicts HIV-RNA rebound and the outcome of highly active antiretroviral therapy.","volume":"18","author":"Hatzakis","year":"2004","journal-title":"AIDS"},{"key":"R16-6-20210130","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1086\/340614","article-title":"Persistence of human immunodeficiency virus (HIV) type 1 DNA in peripheral blood despite prolonged suppression of plasma HIV-1 RNA in children.","volume":"185","author":"Saitoh","year":"2002","journal-title":"J Infect Dis"},{"key":"R17-6-20210130","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1089\/aid.1998.14.1053","article-title":"Cellular proviral HIV type 1 DNA load persists after long-term RT-inhibitor therapy in HIV type 1 infected persons.","volume":"14","author":"Bruisten","year":"1998","journal-title":"AIDS Res Hum Retroviruses"},{"key":"R18-6-20210130","doi-asserted-by":"crossref","first-page":"8869","DOI":"10.1073\/pnas.95.15.8869","article-title":"Early establishment of a pool of latently infected, resting CD4() T cells during primary HIV-1 infection.","volume":"95","author":"Chun","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R19-6-20210130","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1097\/00002030-200104130-00001","article-title":"Proviral HIV-1 DNA in subjects followed since primary HIV-1 infection who suppress plasma viral load after one year of highly active antiretroviral therapy.","volume":"15","author":"Ngo-Giang-Huong","year":"2001","journal-title":"AIDS"},{"key":"R20-6-20210130","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1097\/00002030-199410000-00008","article-title":"Evaluation of proviral copy number and plasma RNA level as early indicators of progression in HIV-1 infection: correlation with virological and immunological markers of disease.","volume":"8","author":"Verhofstede","year":"1994","journal-title":"AIDS"},{"key":"R21-6-20210130","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.1097\/00002030-200012220-00001","article-title":"Decay of cell-associated HIV-1 DNA correlates with residual replication in patients treated during acute HIV-1 infection.","volume":"14","author":"Yerly","year":"2000","journal-title":"AIDS"},{"key":"R22-6-20210130","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1093\/jac\/dkq084","article-title":"Impact of 48 week lopinavirritonavir monotherapy on blood cell-associated HIV-1-DNA in the MONARK trial.","volume":"65","author":"Avettand-Fenoel","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"R23-6-20210130","doi-asserted-by":"crossref","first-page":"e41390","DOI":"10.1371\/journal.pone.0041390","article-title":"Similar evolution of cellular HIV-1 DNA level in darunavirritonavir monotherapy versus triple therapy in MONOI-ANRS136 trial over 96 weeks.","volume":"7","author":"Lambert-Niclot","year":"2012","journal-title":"PLoS One"},{"key":"R24-6-20210130","first-page":"156","article-title":"2011 update of the drug resistance mutations in HIV-1.","volume":"19","author":"Johnson","year":"2011","journal-title":"Top Antivir Med"},{"key":"R26-6-20210130","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1002\/jcla.20307","article-title":"Checklist for optimization and validation of real-time PCR assays.","volume":"23","author":"Raymaekers","year":"2009","journal-title":"J Clin Lab Anal"},{"key":"R27-6-20210130","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1097\/QCO.0b013e32834ef5d9","article-title":"Low-level viraemia on HAART: significance and management.","volume":"25","author":"Doyle","year":"2012","journal-title":"Curr Opin Infect Dis"},{"key":"R28-6-20210130","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1093\/infdis\/jir208","article-title":"Relationship between residual plasma viremia and the size of HIV proviral DNA reservoirs in infected individuals receiving effective antiretroviral therapy.","volume":"204","author":"Chun","year":"2011","journal-title":"J Infect Dis"},{"key":"R29-6-20210130","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.molmed.2004.09.006","article-title":"The multifactorial nature of HIV-1 latency.","volume":"10","author":"Lassen","year":"2004","journal-title":"Trends Mol Med"},{"key":"R30-6-20210130","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1310\/80JH-148K-NADQ-U927","article-title":"Reservoirs, sanctuaries, and residual disease: the hiding spots of HIV-1.","volume":"4","author":"Pomerantz","year":"2003","journal-title":"HIV Clin Trials"},{"key":"R31-6-20210130","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1038\/nm880","article-title":"Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4 T cells.","volume":"9","author":"Siliciano","year":"2003","journal-title":"Nat Med"},{"key":"R32-6-20210130","doi-asserted-by":"crossref","first-page":"11212","DOI":"10.1128\/JVI.77.20.11212-11219.2003","article-title":"Productive infection maintains a dynamic steady state of residual viremia in human immunodeficiency virus type 1-infected persons treated with suppressive antiretroviral therapy for five years.","volume":"77","author":"Havlir","year":"2003","journal-title":"J Virol"},{"key":"R33-6-20210130","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1086\/519428","article-title":"Predictors of virological outcome and safety in primary HIV type 1-infected patients initiating quadruple antiretroviral therapy: QUEST GW PROB3005.","volume":"45","author":"Hoen","year":"2007","journal-title":"Clin Infect Dis"},{"key":"R34-6-20210130","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1086\/345860","article-title":"Predictive value of provirus load and DNA human immunodeficiency virus genotype for successful abacavir-based simplified therapy.","volume":"187","author":"Pellegrin","year":"2003","journal-title":"J Infect Dis"}],"container-title":["AIDS"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/QAD.0000000000000060","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T05:55:43Z","timestamp":1620971743000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00002030-201401140-00006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1,14]]},"references-count":33,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.1097\/qad.0000000000000060","relation":{},"ISSN":["0269-9370"],"issn-type":[{"value":"0269-9370","type":"print"}],"subject":[],"published":{"date-parts":[[2014,1,14]]}}}